HIV and ID Observations

June 2nd, 2012

Cryptococcal Meningitis Study Stopped — Early HIV Therapy Clearly Harmful

From NIAID, an important clinical trial has been stopped early: The Phase IV study … was evaluating whether HIV-infected participants hospitalized with cryptococcal meningitis (CM) but not yet taking antiretroviral therapy (ART) would improve their chances of survival if they began ART while receiving CM treatment as inpatients compared with the standard practice of beginning […]

---

May 30th, 2012

Little Fluffy Baby Chicks Spread Deadly Intestinal Infection

Sorry for the headline, but that was the first thing I thought of when reading this paper just published in the New England Journal of Medicine: In this report, we describe a prolonged and ongoing multistate outbreak of human salmonella infections primarily affecting young children and linked to contact with live young poultry from a […]

---

May 20th, 2012

News on HIV and HCV Testing, and in Praise of Accurate Screening Tests

Two recent news items reminded me how lucky we are to have some very accurate screening tests for certain infectious diseases. The news: An expert FDA panel backed approval of the first true home test for HIV, the OraQuick mouth swab test. Approval of OraQuick for home use may occur later this year. While home […]

---

May 16th, 2012

Azithromycin Linked to Cardiovascular Death — Not A Placebo After All

I’ve commented before about azithromycin, that remarkable antibiotic that clinicians seem to prescribe for, gosh, you-name-it. But a paper just published in the New England Journal of Medicine links use of azithromycin to an increased risk of cardiovascular death, a reminder that “azithro” is in fact a drug — and that all drugs have side […]

---

May 10th, 2012

Advisory Meeting Today on Tenofovir/FTC for PrEP, and a Proposed “Niche” for its Use

From Bloomberg News: Gilead Sciences Inc.’s pill Truvada was safe and effective when used to protect uninfected people from getting HIV, U.S. regulators said in a report indicating the main concerns are when and how it should be used … The FDA asked its advisers to suggest who should get Truvada; what testing would be […]

---

May 7th, 2012

Difficulties and Differences on C difficile

Some things in our field — diseases, treatments, generalizations, cliches, fads — have really changed since back in the early 1990s, when I started in this business. Here are a few that quickly come to mind: “Double coverage” of pseudomonas with a beta lactam plus an aminoglycoside was de rigueur MRSA was an inpatient concern […]

---

April 23rd, 2012

An Answer to a Commonly Asked Question: Is Treatment 100% Effective in Preventing HIV Transmission?

The excitement about “treatment as prevention”, and the results of Study 052, have led to many patients asking the question (if not in these words, than using others with a less medical slant), “So if I’m on treatment and doing well, just what is the risk of my transmitting HIV to others?” It’s not a […]

---

April 18th, 2012

Been There, Done That

I’d estimate the verisimilitude of the following video at approximately 100%: (Thanks to Raphy Landovitz for the link!)

---

April 17th, 2012

EASL Starts Tomorrow — Get Ready for the HCV Treatment Deluge

I can’t think of a single upcoming scientific meeting in ID that’s likely to be more “game changing”  — sorry for the tired metaphor — than the 47th European Association for the Study of the Liver (EASL) meeting, which starts tomorrow in Barcelona. As a hint of what’s to come, earlier this month Abbott released […]

---

April 10th, 2012

A Skeptical Look at “Test and Treat”

Over in Journal Watch AIDS Clinical Care, Abbie Zuger has written a fascinating perspective on the recent enthusiasm for universal HIV treatment. Her take? Let’s just say she doesn’t share the enthusiasm of public health officials and members of guidelines committees. Well, that’s a huge understatement. Specifically: This strategy, which calls for universal voluntary HIV […]

---